Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 33 Publications

6 Customer Reviews

  • (e) c-peptide from these mice 240 min after respective treatments.

    Nature, 2018, 560(7719):499-503. Linsitinib (OSI-906) purchased from Selleck.

    Inhibition of IGF receptor by the IGFR inhibitor linsitinib reduced ERK1/2 signaling activation particularly in U87MG RG7388 resistant cells.

    Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-1580. Linsitinib (OSI-906) purchased from Selleck.

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk M3LkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMEK4NFYh|ryP MYfTRW5ITVJ?
KS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPrTWM2OD1yLkCzPFM2KM7:TR?= NH;pXpRUSU6JRWK=
TE-11 NUH3Z4lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEe4NlIh|ryP M{m0cHNCVkeHUh?=
EW-1 NGjIN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr3fI9KSzVyPUCuNFg2QDVizszN MWfTRW5ITVJ?
HMV-II NHLtcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTiTWM2OD1yLkC4PFQ3KM7:TR?= NHnvfYhUSU6JRWK=
COLO-205 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\QcIQ6UUN3ME2wMlExPDV2IN88US=> MoDhV2FPT0WU
ES1 NEPjSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjldVBKSzVyPUCuNVA3QTZizszN NG[4ZWNUSU6JRWK=
GDM-1 M4\TU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMUO2O|Ih|ryP MWrTRW5ITVJ?
ML-2 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMUW4PVYh|ryP M{H6eHNCVkeHUh?=
Saos-2 MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMU[1NlYh|ryP NWLK[|NxW0GQR1XS
NCI-H1355 MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjjTWM2OD1yLkG4NVM2KM7:TR?= MmnPV2FPT0WU
G-401 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMUiyN{DPxE1? NUP4UFFzW0GQR1XS
EW-16 M2DYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK2fFJXUUN3ME2wMlE5Pzd5IN88US=> MXPTRW5ITVJ?
EW-7 MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDXe5FQUUN3ME2wMlE5QDhzIN88US=> NFy2To9USU6JRWK=
NCI-H727 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXsUmJEUUN3ME2wMlE6Pzl2IN88US=> MYXTRW5ITVJ?
LCLC-97TM1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnVW2Y4UUN3ME2wMlIxQTV3IN88US=> NX3t[XlGW0GQR1XS
NCI-H650 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPrTWM2OD1yLkKxN|g1KM7:TR?= M2j2T3NCVkeHUh?=
NCI-H2122 Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXsWnJKSzVyPUCuNlMzQTlizszN M2S0RXNCVkeHUh?=
SK-N-DZ NX\sS3ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fnXmlEPTB;MD6yN|Y6QCEQvF2= M1W3PXNCVkeHUh?=
HT-29 MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3nSnBnUUN3ME2wMlI1OjR6IN88US=> MWnTRW5ITVJ?
LB771-HNC NHm5RpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO0TWM2OD1yLkK1PVE2KM7:TR?= NHe5e3JUSU6JRWK=
HT-144 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmOwTWM2OD1yLkK2NVkyKM7:TR?= NUTRWI4{W0GQR1XS
LAN-6 NIWzNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnJWYRKSzVyPUCuNlY{PDhizszN MkK4V2FPT0WU
EW-18 NEHpW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL4NpdKSzVyPUCuNlcxODFizszN MVLTRW5ITVJ?
LS-1034 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nMXGlEPTB;MD6yO|E{OiEQvF2= M1eze3NCVkeHUh?=
EW-11 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDESI5KSzVyPUCuNlg1OzJizszN MmW2V2FPT0WU
SNU-C1 M4rnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzHZVAxUUN3ME2wMlI6OzF|IN88US=> MY\TRW5ITVJ?
RS4-11 NG\BXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDufnVKSzVyPUCuN|M4PThizszN NWLmUmFuW0GQR1XS
ES4 NFnnfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwNEGwN|gh|ryP M2PQZnNCVkeHUh?=
COLO-320-HSR M4nFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X5Z2lEPTB;MD60NVM3QCEQvF2= NFK0UItUSU6JRWK=
NB10 NFK1V4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3OwW2lEPTB;MD60OVQ{PyEQvF2= MoPYV2FPT0WU
BFTC-905 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm5ZW1KSzVyPUCuOFY4PThizszN M4\MR3NCVkeHUh?=
A375 NF:xZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX5dFZKSzVyPUCuOFc3OTdizszN MVrTRW5ITVJ?
SJRH30 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInqdJFKSzVyPUCuOVA5OjJizszN NXLOWm0{W0GQR1XS
NOS-1 NUSzcmY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwNUKyOlch|ryP MnK1V2FPT0WU
SIG-M5 NHzLTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfaUW9KSzVyPUCuOVM2PTdizszN M1\HXHNCVkeHUh?=
DOK NWP3fIFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHuUJlKSzVyPUCuOVU3KM7:TR?= MlHYV2FPT0WU
NB69 MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljjTWM2OD1yLkW4NlU4KM7:TR?= M4HyTHNCVkeHUh?=
SK-NEP-1 M3\UT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\5cmlEPTB;MD62NFI{PiEQvF2= NW\sXGsxW0GQR1XS
SK-MM-2 NHHvTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\4TWM2OD1yLk[1OFkyKM7:TR?= M2fVPXNCVkeHUh?=
NCI-H358 MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwNkewPFIh|ryP MoDMV2FPT0WU
RH-1 M1q3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4n5OWlEPTB;MD63OFg2QSEQvF2= NUPOTGtuW0GQR1XS
NH-12 NFjRW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTVTWM2OD1yLke2NFQ3KM7:TR?= MljnV2FPT0WU
TE-12 NW\aSIZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vtUWlEPTB;MD63OlQ5PiEQvF2= NFzacppUSU6JRWK=
COLO-668 Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfiWnl1UUN3ME2wMlg1PjZ4IN88US=> MUjTRW5ITVJ?
PANC-08-13 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDlTWM2OD1yLki2N|c4KM7:TR?= NIPaSHRUSU6JRWK=
HCC2998 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHqTWM2OD1yLki4NlY{KM7:TR?= MV;TRW5ITVJ?
ABC-1 NI\PUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT6flI6UUN3ME2wMlkxOzV{IN88US=> Mn21V2FPT0WU
ES6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS1TWM2OD1yLkmxNFY3KM7:TR?= MoruV2FPT0WU
SNU-387 NYPvfFdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwOUmzPVMh|ryP MYfTRW5ITVJ?
CMK NGn4bHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnX[nNKSzVyPUCuPVk6OjlizszN NFXKUHBUSU6JRWK=
SJSA-1 NW\V[G5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwMEO2OVMh|ryP MVnTRW5ITVJ?
SIMA NIHtRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TFbmlEPTB;MT6wOlgzPSEQvF2= MV7TRW5ITVJ?
ES3 Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TWVGlEPTB;MT6xNlI6PyEQvF2= MmHRV2FPT0WU
IGROV-1 M1uzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PKS2lEPTB;MT6xOVQ1PCEQvF2= MWfTRW5ITVJ?
MEL-JUSO MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMUW3OVkh|ryP NXX6XZF3W0GQR1XS
T84 M1voWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\RSmlEPTB;MT6yNFkyPCEQvF2= M4G4d3NCVkeHUh?=
CAL-85-1 M4C4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrXZ2FKSzVyPUGuNlMyOzhizszN MYPTRW5ITVJ?
RD MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPkZlNKSzVyPUGuNlY1PTVizszN MVfTRW5ITVJ?
TE-8 M1\vT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi5bIlQUUN3ME2xMlMyPDZ{IN88US=> MWLTRW5ITVJ?
L-363 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1GwcmlEPTB;MT6zOFIxQCEQvF2= MYHTRW5ITVJ?
EKVX MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPqUo5KSzVyPUGuN|Q2PjhizszN MUjTRW5ITVJ?
SK-MEL-3 NGrFUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fP[mlEPTB;MT60PFU2PiEQvF2= M1vGSXNCVkeHUh?=
TGBC24TKB MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj1doY1UUN3ME2xMlUxOTl|IN88US=> NHm5O4ZUSU6JRWK=
NCI-H1770 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwNUGxNVMh|ryP MlzBV2FPT0WU
HuH-7 NIPrS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTPTWM2OD1zLk[wNFk5KM7:TR?= MlHVV2FPT0WU
HL-60 M2fEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH4TWM2OD1zLk[2PVI5KM7:TR?= NWS2fGFjW0GQR1XS
TE-1 NIXaVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS4TWM2OD1zLkewPVQ2KM7:TR?= MXHTRW5ITVJ?
LC-2-ad NFvCZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;Ec4dKSzVyPUGuO|M5QDdizszN MXfTRW5ITVJ?
LB647-SCLC MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTtOmU2UUN3ME2xMlc3PTh|IN88US=> MkXvV2FPT0WU
NCI-H2171 MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTFwN{e3NVYh|ryP NX;OVGFFW0GQR1XS
SK-PN-DW NEfVWXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnQOWxlUUN3ME2xMlkyOjl6IN88US=> M1;hU3NCVkeHUh?=
MC-IXC NUnvNoFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom3TWM2OD1zLkm4PVgh|ryP NGjEcItUSU6JRWK=
LS-513 NUjuV4hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP1TWM2OD1{LkC1N|A2KM7:TR?= MVTTRW5ITVJ?
EW-3 NGTENWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X3UWlEPTB;Mj6wPVg1PCEQvF2= Ml\yV2FPT0WU
OPM-2 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJwMUCyJO69VQ>? MWTTRW5ITVJ?
LP-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDmVZhKSzVyPUKuNlU5ODdizszN MlHJV2FPT0WU
LU-134-A NYnWW3NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJwMke3JO69VQ>? MWHTRW5ITVJ?
CP66-MEL MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnXU45KSzVyPUKuNlkxOTRizszN MYTTRW5ITVJ?
HCC1143 NFnTdGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\XN5hqUUN3ME2yMlQ2OzZ6IN88US=> NGDWW2tUSU6JRWK=
LOXIMVI NXzybmJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPRTWM2OD1{Lk[wNlEh|ryP NYjG[2I{W0GQR1XS
TE-10 NGfZUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJwN{C4N|gh|ryP NInQS3dUSU6JRWK=
NCI-H1882 NYKwTIMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7ITWM2OD1{Lke1NlI4KM7:TR?= M3LkbHNCVkeHUh?=
CHP-126 NV7HNG1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M372TWlEPTB;Mj63OlMyPyEQvF2= NGLq[ZVUSU6JRWK=
NCI-H1623 NWnkNIdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJwOUKwNlQh|ryP MoXuV2FPT0WU
GB-1 MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJwOUO0NFQh|ryP NEf0b5dUSU6JRWK=
RCC10RGB NFPKdINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\kTWM2OD1{Lkm1NlgyKM7:TR?= M1XrVnNCVkeHUh?=
NCI-H2141 MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XpeWlEPTB;Mj65Olg6PiEQvF2= MorDV2FPT0WU
GI-ME-N M{G4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr5TWM2OD1|LkCwOVY2KM7:TR?= M2LvTnNCVkeHUh?=
NCI-H526 M13OOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTNwMESwPFUh|ryP M3nvTXNCVkeHUh?=
NCI-H747 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPQTWM2OD1|LkC0PVkzKM7:TR?= MoToV2FPT0WU
SNU-423 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\jUGlEPTB;Mz6yNFMyOyEQvF2= NUTISWxjW0GQR1XS
A427 NIj0OlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fZfGlEPTB;Mz6yOVY6QSEQvF2= MX7TRW5ITVJ?
CAL-12T NVnKbnVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNwNEC3NVMh|ryP NXXBNYtNW0GQR1XS
LU-99A MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjBR5RKSzVyPUOuOFcyODVizszN NXHlfVV5W0GQR1XS
MS-1 M{HuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPTTWM2OD1|LkWzOFI6KM7:TR?= M3vhdnNCVkeHUh?=
SK-LU-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jzRmlEPTB;Mz63OlI6PSEQvF2= MnzwV2FPT0WU
SW837 M3fpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DE[WlEPTB;Mz63OlM{OyEQvF2= MkjDV2FPT0WU
ES8 NFnyS|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDmTWM2OD1|LkizPFc4KM7:TR?= NHrLOm1USU6JRWK=
MZ2-MEL MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HmSWlEPTB;Mz65NlA5PiEQvF2= MUfTRW5ITVJ?
TGW NGrNb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnWTWM2OD12LkCxN|EyKM7:TR?= NWXUcVdJW0GQR1XS
GP5d NEXpZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nPNWlEPTB;ND6wOVM3OiEQvF2= NIK4OmJUSU6JRWK=
BB49-HNC Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[yTZV6UUN3ME20MlE2OjF|IN88US=> MX7TRW5ITVJ?
NB13 NFz5S4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jIbWlEPTB;ND6yOlg5PyEQvF2= MYLTRW5ITVJ?
NTERA-S-cl-D1 M1vVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHWVVJKSzVyPUSuNlg3OTVizszN MVnTRW5ITVJ?
NCI-H1648 M3jpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16xNGlEPTB;ND6yPVgyQSEQvF2= NVnveVE4W0GQR1XS
LCLC-103H NHjwSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPrTWM2OD12LkOyNVk2KM7:TR?= NEPxUWZUSU6JRWK=
LS-411N NXfBbG1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nHZmlEPTB;ND60OFg5PSEQvF2= MXPTRW5ITVJ?
NCI-H1092 NITwXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TMO2lEPTB;ND60OVY5PyEQvF2= MYPTRW5ITVJ?
PANC-10-05 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzxTWM2OD12Lk[5PFQh|ryP MW\TRW5ITVJ?
DK-MG M1PaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\QbWlEPTB;ND64NFk{OyEQvF2= NULocmlWW0GQR1XS
OVCAR-5 M17qTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\pVWlEPTB;ND64NVIzPiEQvF2= NF3qbXRUSU6JRWK=
CAL-39 NXXP[mJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfUXZBKSzVyPUSuPFc3PyEQvF2= NX\3emhUW0GQR1XS
TE-441-T NIr5UHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH3TWM2OD12LkmwOVM4KM7:TR?= NY\MepY{W0GQR1XS
MOLT-16 M2S2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe4RmhKSzVyPUSuPVUzPTNizszN NWXFV|Y{W0GQR1XS
MCF7 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPwXGZKSzVyPUWuNVQ2OTdizszN MmTJV2FPT0WU
CAPAN-1 NVXKW2czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX3ZphxUUN3ME21MlI2PzB5IN88US=> M{mydXNCVkeHUh?=
PSN1 NEDxWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW2[4lEUUN3ME21MlI4OjN3IN88US=> MmrMV2FPT0WU
NCI-H292 NF\4W2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfaTWM2OD13LkOwNFQ1KM7:TR?= NFTzdZhUSU6JRWK=
CPC-N MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTVwM{m0NVkh|ryP NF;SUlRUSU6JRWK=
DoTc2-4510 MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;jTWM2OD13LkS1N|cyKM7:TR?= M17HUXNCVkeHUh?=
LB1047-RCC MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WzeGlEPTB;NT61OVk{OyEQvF2= M1PxNXNCVkeHUh?=
MHH-ES-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDLe4p2UUN3ME21MlU6QTB5IN88US=> NWnoc4h6W0GQR1XS
NMC-G1 M1HrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPRTWM2OD13LkewNlI4KM7:TR?= M2fHeXNCVkeHUh?=
SW1710 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTVwN{S3OVEh|ryP MnjPV2FPT0WU
YAPC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPIVnpnUUN3ME21Mlc3OjBzIN88US=> MUjTRW5ITVJ?
22RV1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDOfpJKSzVyPUWuPFAxOTlizszN MoewV2FPT0WU
COLO-679 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTVwOEi5OFgh|ryP NF;ZbYVUSU6JRWK=
TCCSUP M3rHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTVwOUOyOVkh|ryP NVqwSo1vW0GQR1XS
C2BBe1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTVwOUO5O{DPxE1? M2TaO3NCVkeHUh?=
TE-15 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXtdJNKSzVyPU[uNFY3ODVizszN MofKV2FPT0WU
SCLC-21H NVP1O5dTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvNTWM2OD14LkGwPFQ{KM7:TR?= NVS0cYNLW0GQR1XS
EoL-1-cell MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrnTWM2OD14LkG2OVY{KM7:TR?= MXHTRW5ITVJ?
NKM-1 NXXFd2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn1c|NFUUN3ME22MlE3PzFizszN MnfnV2FPT0WU
NCI-H1304 M{GwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\tTWM2OD14LkK3OFI5KM7:TR?= MX\TRW5ITVJ?
NB6 M4KwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\OTWM2OD14LkK5OlIzKM7:TR?= NXj2Umg5W0GQR1XS
NALM-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTZwM{OyN{DPxE1? MljmV2FPT0WU
NCI-H522 M2jQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTZwM{OzNFYh|ryP MUfTRW5ITVJ?
MV-4-11 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3CfYRoUUN3ME22MlM4ODd7IN88US=> M4r2[XNCVkeHUh?=
LB2241-RCC M2Xidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\ITWNKSzVyPU[uN|g3PjdizszN NVTIe2NZW0GQR1XS
NCI-H1417 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DPXmlEPTB;Nj60NFg1PyEQvF2= MXzTRW5ITVJ?
HT-1197 NUDndpdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLTR49KSzVyPU[uOVcyOjJizszN MlH5V2FPT0WU
P30-OHK MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVW4UItTUUN3ME22MlYzPzdizszN MmLXV2FPT0WU
ALL-PO MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[1TWM2OD14LkexPVE3KM7:TR?= MnHxV2FPT0WU
OVCAR-4 NXvTd41ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn4V5pKSzVyPU[uO|U1ODVizszN MlHhV2FPT0WU
HCC2157 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTZwN{e0O|Uh|ryP MWDTRW5ITVJ?
NCI-H838 NF\WTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;rVGlEPTB;Nj65OlQ6KM7:TR?= MkO0V2FPT0WU
NCI-H1299 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTxVnVTUUN3ME22Mlk4ODlizszN NFfGRldUSU6JRWK=
SW954 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:yXWtKSzVyPUeuNlAxPjhizszN MYXTRW5ITVJ?
NCI-H441 M{LyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHtfXM1UUN3ME23MlM1ODZ3IN88US=> M4DBbnNCVkeHUh?=
SK-MEL-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T6UmlEPTB;Nz60PFM4OyEQvF2= MlXrV2FPT0WU
KARPAS-45 MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M375TmlEPTB;Nz62OVkzQSEQvF2= NXfDZXN4W0GQR1XS
CAL-54 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TTRmlEPTB;Nz64Nlk4PyEQvF2= NH7jN5pUSU6JRWK=
KYSE-180 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTdwOEi5OFEh|ryP M2XmRXNCVkeHUh?=
NCI-H187 M1LH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\QZ2lEPTB;Nz65OVk1PyEQvF2= M13qenNCVkeHUh?=
RT-112 MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rsdGlEPTB;OD6wPVY4PyEQvF2= NVWzeYpVW0GQR1XS
NCI-H1437 NEDuRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWqxVnVsUUN3ME24MlA6Pzl3IN88US=> MWrTRW5ITVJ?
SNU-449 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:2[FI5UUN3ME24MlI5Ojd{IN88US=> MWTTRW5ITVJ?
HCC1187 NXT5RlZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDN[IhKSzVyPUiuNlk{QTFizszN NFfSfZFUSU6JRWK=
NCI-H2030 NUPB[|JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Hsc2lEPTB;OD6zO|cyPCEQvF2= M{jwenNCVkeHUh?=
HuO-3N1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRThwM{e4OFQh|ryP NXfSSVhwW0GQR1XS
COLO-792 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon4TWM2OD16LkSxOVI4KM7:TR?= MWHTRW5ITVJ?
MIA-PaCa-2 M1r6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRThwOEW1NFgh|ryP NIX4c3dUSU6JRWK=
SK-N-FI NF21SnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DxXGlEPTB;OT6wOFI2KM7:TR?= NFrRWW9USU6JRWK=
MMAC-SF NXHBZW12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTlwMEm3OVEh|ryP MkPpV2FPT0WU
NCI-H28 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfHR|RvUUN3ME25MlExPDZ7IN88US=> MofQV2FPT0WU
ETK-1 MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX5TWM2OD17LkK5PVc1KM7:TR?= M2fj[3NCVkeHUh?=
NCI-H1993 NUDRdGZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fBcWlEPTB;OT60OFI3OSEQvF2= MlG4V2FPT0WU
no-11 Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrOWFlKSzVyPUmuOFcyOiEQvF2= NYXPV2J[W0GQR1XS
ChaGo-K-1 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTlwNUG1PFMh|ryP MXPTRW5ITVJ?
NCCIT NIDLcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TwemlEPTB;OT61N|E3QSEQvF2= MWXTRW5ITVJ?
SAS NYLLSYRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33vWWlEPTB;MUCuNlQ5KM7:TR?= MXTTRW5ITVJ?
A673 M1XOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTaTWM2OD1zMD6zO|A1KM7:TR?= NX[3bnNsW0GQR1XS
NCI-H1522 NEXBeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfLOnd3UUN3ME2xNE4{PzB5IN88US=> NVj2WnlEW0GQR1XS
NCI-H810 NIXMTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFyLkO5NFch|ryP MkeyV2FPT0WU
IST-MES1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jDRmlEPTB;MUCuOFU3PCEQvF2= NUXQdlRnW0GQR1XS
GR-ST NEHZV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjvbGpKSzVyPUGwMlUxOjRizszN MYnTRW5ITVJ?
SUP-T1 NXXFXlVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrmUJBKSzVyPUGwMlc{OTdizszN NWXue|NuW0GQR1XS
NB5 M4f1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDJblBrUUN3ME2xNE46ODJ{IN88US=> MUDTRW5ITVJ?
MZ1-PC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHZTWM2OD1zMD65OVcyKM7:TR?= NEXrbHpUSU6JRWK=
SK-CO-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XX[WlEPTB;MUCuPVk{OSEQvF2= M{DpeHNCVkeHUh?=
Capan-2 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm1XYpKSzVyPUGxMlMyQThizszN NH64U2RUSU6JRWK=
697 MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFzLk[3OVch|ryP NEW2[Y1USU6JRWK=
REH M{[0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ONlU6UUN3ME2xNU44PDVzIN88US=> NWe4cY5lW0GQR1XS
GI-1 M3nMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjOfYtKSzVyPUGxMlg3OTVizszN NEiy[mVUSU6JRWK=
BB65-RCC NVfMeIYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLCdFRKSzVyPUGyMlA6OTZizszN MXLTRW5ITVJ?
NCI-H1651 MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi1S5VoUUN3ME2xNk4zPDd6IN88US=> NFHD[IRUSU6JRWK=
NCI-H1618 NGjrRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\Bc2lEPTB;MUKuN|k4PiEQvF2= NEPrNFdUSU6JRWK=
NCI-H2081 NELW[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET0RYxKSzVyPUGyMlYyPDFizszN MmD1V2FPT0WU
GCIY MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF{LkeyNVMh|ryP M13CfnNCVkeHUh?=
NY MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL2TWM2OD1zMz6wOlQ{KM7:TR?= M3y1S3NCVkeHUh?=
PANC-03-27 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF|LkC4NFch|ryP NIDk[FJUSU6JRWK=
BHY MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i4cmlEPTB;MUOuNlEzOSEQvF2= NHvDV3JUSU6JRWK=
SK-OV-3 M{PiXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPoS45KSzVyPUGzMlM4PjNizszN NGr4fFZUSU6JRWK=
5637 NV74OXViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\mWmJqUUN3ME2xN{44PzV7IN88US=> MXXTRW5ITVJ?
LC-1F NUTQbolzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF2LkCzOVYh|ryP MnXqV2FPT0WU
SNB75 NFK4OWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDrTWM2OD1zND6wN|g{KM7:TR?= NVG4SIE6W0GQR1XS
CHP-212 Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC4TWM2OD1zND6wOFY1KM7:TR?= M13iT3NCVkeHUh?=
HT-1376 NXW1V4ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHzPG12UUN3ME2xOE4yOTJ4IN88US=> MULTRW5ITVJ?
MONO-MAC-6 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C2OWlEPTB;MUSuNVUxOiEQvF2= M1LmNXNCVkeHUh?=
CA46 M{j0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF2LkG4Nlch|ryP NFTiOopUSU6JRWK=
SCC-15 MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LVNWlEPTB;MUSuOVU5OyEQvF2= MXvTRW5ITVJ?
ATN-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnBUHV{UUN3ME2xOE43PjJ5IN88US=> MYjTRW5ITVJ?
NCI-H2405 NF7NNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF2LkixOVch|ryP NYLzOXVmW0GQR1XS
NCI-H716 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ew[mlEPTB;MUSuPFQ6OyEQvF2= NFX0fIZUSU6JRWK=
SW620 NWDRdWgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\weoJKSzVyPUG0MlkxOTRizszN NVXaW5JlW0GQR1XS
NCI-H226 MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe5OoNKSzVyPUG0MlkxQDVizszN NIL0XYdUSU6JRWK=
SW962 M2PKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF2Lkm0N|Ih|ryP MYLTRW5ITVJ?
KYSE-150 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\KWIpKSzVyPUG0Mlk2PSEQvF2= MmC1V2FPT0WU
OCUB-M M4rkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHFUopKSzVyPUG0Mlk5QDNizszN NUDTcmlOW0GQR1XS
ES7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXKOlBwUUN3ME2xOU4xQTh2IN88US=> NGDsOItUSU6JRWK=
SW1463 M{Dq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW2TWM2OD1zNT60NlI{KM7:TR?= NHT2OYxUSU6JRWK=
CAKI-1 M{jFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF3LkWzOFYh|ryP NIXG[25USU6JRWK=
MKN28 NWTS[21PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fobmlEPTB;MUWuOVQ4QSEQvF2= NFvMTJFUSU6JRWK=
SW13 NIfvSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTYSWtnUUN3ME2xOU43OThizszN NIPwRnFUSU6JRWK=
A3-KAW M1fkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnleZdKSzVyPUG1Mlk3QTdizszN NV\5dpp7W0GQR1XS
LU-65 NYDVSYR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPrTWM2OD1zNT65O|Y5KM7:TR?= M2r3bnNCVkeHUh?=
Calu-1 M1;kN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\0Z2lEPTB;MU[uNFM3QCEQvF2= NIDtOHpUSU6JRWK=
ST486 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF4LkC0N|Eh|ryP NGTiVG1USU6JRWK=
BB30-HNC NEiwUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF4LkGyOFYh|ryP NU\QUG8zW0GQR1XS
EGI-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHG5XpNKSzVyPUG2MlQ1PiEQvF2= MUDTRW5ITVJ?
SH-4 M4LBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDYTWM2OD1zNj60O|MyKM7:TR?= NUHk[oxUW0GQR1XS
MN-60 NHPPeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LpNGlEPTB;MUeuNlI6PyEQvF2= NX\6Zpc6W0GQR1XS
MPP-89 MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF5LkK0OVkh|ryP MnLnV2FPT0WU
A2780 NG[xfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL4TWM2OD1zNz60NVM6KM7:TR?= M360dXNCVkeHUh?=
Daoy NEHwT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTXRW57UUN3ME2xO{41Pjl3IN88US=> NILVNHdUSU6JRWK=
NCI-H2126 NUXv[nJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LKfWlEPTB;MUeuOFc4OSEQvF2= M{jHdXNCVkeHUh?=
NCI-H1563 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zHe2lEPTB;MUeuOFkyPyEQvF2= NX7BfY02W0GQR1XS
8-MG-BA M2jGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknrTWM2OD1zNz62OlQ5KM7:TR?= MlvxV2FPT0WU
786-0 NHvwWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITQSXdKSzVyPUG3Mlg{PTNizszN NFnCTVVUSU6JRWK=
AM-38 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF5LkmzNFYh|ryP NV;WSWdJW0GQR1XS
COLO-824 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jqWWlEPTB;MUiuOFQ{PiEQvF2= NEGxUoZUSU6JRWK=
SK-MEL-30 NEXiWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXRTWM2OD1zOD61NFgzKM7:TR?= MknqV2FPT0WU
CESS M4fhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP0TWM2OD1zOD63OlA6KM7:TR?= MoXwV2FPT0WU
BL-70 M1y5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DQb2lEPTB;MUiuPFE2PiEQvF2= MmjmV2FPT0WU
NCI-H2170 NYf4UmhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH74WWdKSzVyPUG4MlkyPzlizszN NHHqcJhUSU6JRWK=
HT-3 MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr0fHhxUUN3ME2xPE46QDNizszN MkXYV2FPT0WU
BOKU NF:3OFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULHTZpZUUN3ME2xPU4xOzhzIN88US=> MofWV2FPT0WU
HPAF-II M17zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i1RWlEPTB;MUmuN|AyPSEQvF2= NVrWSod7W0GQR1XS
KGN NV;mdZlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF7LkS3OlUh|ryP NXLwO414W0GQR1XS
MC-CAR MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL6TWM2OD1zOT62N|E{KM7:TR?= M3rw[XNCVkeHUh?=
BHT-101 NHPVW|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nOcWlEPTB;MUmuO|c4KM7:TR?= NGXp[mNUSU6JRWK=
SW1783 NVfnU5RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTjeZFEUUN3ME2xPU44QDB4IN88US=> NUTnZYpiW0GQR1XS
KP-N-YN M{\Y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJyLkCyOlIh|ryP NGP6flBUSU6JRWK=
LU-165 M4LPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJyLkW1O|Eh|ryP MkG2V2FPT0WU
GOTO M4LwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fQV2lEPTB;MkCuOlQ2OSEQvF2= NXjiRppTW0GQR1XS
EFM-19 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJzLkC3NVYh|ryP MY\TRW5ITVJ?
CTV-1 NFjVd5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nkZmlEPTB;MkGuNVA2PCEQvF2= NXy2cHRbW0GQR1XS
HEL Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOxTWM2OD1{MT60NlE3KM7:TR?= NFv5O4NUSU6JRWK=
SNU-C2B M4nHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PwWGlEPTB;MkGuOFI3KM7:TR?= NEiwNo5USU6JRWK=
ECC4 NGCzTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm5bWZCUUN3ME2yNU44ODdizszN MYXTRW5ITVJ?
NEC8 NIq0XnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJzLkizOlgh|ryP MWjTRW5ITVJ?
KMOE-2 NGTWXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJzLki5NlEh|ryP NYfONJNZW0GQR1XS
NCI-H524 MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJ{LkC4NFgh|ryP NXLPNXc2W0GQR1XS
WSU-NHL MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L5[mlEPTB;MkKuNVU4PyEQvF2= NUDhd4ljW0GQR1XS
SF126 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PmZWlEPTB;MkKuNlQ3QSEQvF2= M2i0dnNCVkeHUh?=
HOP-92 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTX[JdYUUN3ME2yNk4{OTZ5IN88US=> MUXTRW5ITVJ?
CTB-1 NX;LbopWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[2TWM2OD1{Mj60Olc4KM7:TR?= M4LHSXNCVkeHUh?=
KYSE-270 NX\4R4VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJ{LkmzOVch|ryP NUjkVFNSW0GQR1XS
SK-MEL-24 NYO0SldyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jpOGlEPTB;MkOuNVg4KM7:TR?= MYfTRW5ITVJ?
Calu-3 NGnPXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPDTWM2OD1{Mz6yNVI5KM7:TR?= MmfRV2FPT0WU
GAMG NFvYWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfOWGxKSzVyPUKzMlI{PjdizszN MYjTRW5ITVJ?
SW1573 MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLsUYJKSzVyPUKzMlc1OTVizszN NVzTTHdPW0GQR1XS
MHH-NB-11 NXKwc25UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm0bYtKSzVyPUK0MlAyQTRizszN M3jKVnNCVkeHUh?=
TK10 NV20UmZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O4OmlEPTB;MkSuOVAyOyEQvF2= NFv1fZlUSU6JRWK=
LB373-MEL-D NV7VT|l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL3TWM2OD1{ND62NFY1KM7:TR?= NI\yXFBUSU6JRWK=
KALS-1 M3uxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfPSoNmUUN3ME2yOE44OzJ5IN88US=> M1\vfnNCVkeHUh?=
HUTU-80 M2\Z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfM[|dKSzVyPUK1MlgxOzJizszN M1ryXHNCVkeHUh?=
HuP-T3 NEDhR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfmTWM2OD1{Nj6xOlc1KM7:TR?= M4K3SnNCVkeHUh?=
OE19 M{j6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D5b2lEPTB;Mk[uNlE2OyEQvF2= NUeyd4dOW0GQR1XS
J82 NYTwW3F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjXbXZUUUN3ME2yOk4zPDdzIN88US=> Mnz3V2FPT0WU
DU-4475 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJ4LkO4NVkh|ryP M2TOb3NCVkeHUh?=
DMS-53 M3:1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHjPJA1UUN3ME2yOk42OTN6IN88US=> NITBUolUSU6JRWK=
COLO-741 M{KzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnzSnJlUUN3ME2yOk45OzR2IN88US=> NUXGOZViW0GQR1XS
SW48 M1\od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfr[I1QUUN3ME2yOk45QDJizszN NXvlOGJlW0GQR1XS
IGR-1 NF;uVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJ4LkmzN|Qh|ryP MYPTRW5ITVJ?
639-V M2LsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MluyTWM2OD1{Nz6wNlQ2KM7:TR?= Ml3aV2FPT0WU
LK-2 NX;HWlNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnIbVY1UUN3ME2yO{41OTRzIN88US=> NX\FXlR[W0GQR1XS
NCI-H2347 NUTDeIpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX3TWM2OD1{Nz65Olk6KM7:TR?= NXT1cZFuW0GQR1XS
NCI-H2228 NV3ycFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\LWYdkUUN3ME2yPE4xQTB3IN88US=> NGLGUGZUSU6JRWK=
LS-123 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXpWlI3UUN3ME2yPE4yOjZ{IN88US=> M2S1fXNCVkeHUh?=
U031 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW0cYVyUUN3ME2yPE4zPTJizszN MXPTRW5ITVJ?
NCI-H1792 MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljTTWM2OD1{OD60O|IyKM7:TR?= MnTnV2FPT0WU
NCI-H2087 M1PYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHVWWJzUUN3ME2yPE44PTV{IN88US=> M4e5dHNCVkeHUh?=
NCI-H2342 NVnFTmJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmeyTWM2OD1{OT61NlA5KM7:TR?= M2TtdnNCVkeHUh?=
SW626 MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrLTWM2OD1{OT63OVYh|ryP NUWzTJpPW0GQR1XS
LB2518-MEL NXrsUIxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjPfYNKSzVyPUK5MlgyPSEQvF2= MYnTRW5ITVJ?
RXF393 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC1N|FKSzVyPUOwMlA6PTJizszN NHS2fIxUSU6JRWK=
LC4-1 NInJbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTNyLkOwPVIh|ryP MXTTRW5ITVJ?
NCI-H1694 NYTBNGcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTNyLk[2NlQh|ryP NIDYOWhUSU6JRWK=
K5 NXLyVmY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3izWmlEPTB;M{CuPVcxOiEQvF2= NVPnXodZW0GQR1XS
HDLM-2 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LMNGlEPTB;M{CuPVczPSEQvF2= NX33TXJsW0GQR1XS
BCPAP M{fwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPrNWlKSzVyPUOxMlg{PzlizszN NX7idI1jW0GQR1XS
BC-3 NXvjWmpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nvNWlEPTB;M{KuNVQxOyEQvF2= NV:0SIptW0GQR1XS
LB996-RCC NGfRO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETyc29KSzVyPUOyMlI{PThizszN NXnW[JhEW0GQR1XS
NCI-H2009 NX7HZ2MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTN{LkS5PFEh|ryP NH\TXGtUSU6JRWK=
HTC-C3 NV7aUVZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPSZpVKUUN3ME2zN{44PTF7IN88US=> NUTVbJVLW0GQR1XS
LAMA-84 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN2LkS0NFch|ryP NXyyT48xW0GQR1XS
CCRF-CEM NHHNcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\BTWM2OD1|ND61O|E2KM7:TR?= NXTTZoE3W0GQR1XS
AN3-CA MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\GTWM2OD1|NT6wOVY5KM7:TR?= MYTTRW5ITVJ?
NCI-H1734 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTN3LkK1OlEh|ryP NY\5TmplW0GQR1XS
Ca-Ski NFS2[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX5fVBmUUN3ME2zOU41OTBzIN88US=> NIi5SXRUSU6JRWK=
U-266 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HURmlEPTB;M{WuOlEyPCEQvF2= M1;U[HNCVkeHUh?=
SBC-5 M1uze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HtOGlEPTB;M{WuO|c5OSEQvF2= M1LO[HNCVkeHUh?=
GT3TKB MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnrOHlbUUN3ME2zO{4yOTVizszN MVjTRW5ITVJ?
MDA-MB-175-VII NIDSVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTN5LkKyOFgh|ryP M{DicHNCVkeHUh?=
PFSK-1 NH3m[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPBVo9WUUN3ME2zO{4zPDN3IN88US=> M2LueHNCVkeHUh?=
IMR-5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG4N2NKSzVyPUO3MlI1QDdizszN NX\jbXdOW0GQR1XS
Daudi M3rnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN5LkO1PVch|ryP M4Xpc3NCVkeHUh?=
A498 NF\jVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPSTWM2OD1|Nz63NlE5KM7:TR?= MULTRW5ITVJ?
SCC-4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjBTmx{UUN3ME2zO{44QDR|IN88US=> M32ydHNCVkeHUh?=
COLO-680N Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjs[4FHUUN3ME2zPE4zQDh3IN88US=> NYDHbpRjW0GQR1XS
SK-MES-1 NV3idWk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET1OolKSzVyPUO4MlMzOTVizszN NVW4Znc3W0GQR1XS
SR M2TwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e3XGlEPTB;M{iuOVQ6PSEQvF2= NETPdFZUSU6JRWK=
LNCaP-Clone-FGC M3f4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\RZ|RMUUN3ME2zPE42PjN5IN88US=> NXzKUnhSW0GQR1XS
SK-HEP-1 NHzoToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD1TWM2OD1|OD63PFIzKM7:TR?= NIKzdnBUSU6JRWK=
BPH-1 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDVXZNKSzVyPUO4Mlg{OjlizszN MnLIV2FPT0WU
NCI-H1755 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTN7LkW4NVch|ryP NYnGZmpOW0GQR1XS
LXF-289 M2rS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTN7LkiwPFQh|ryP NESxbpJUSU6JRWK=
SW1088 M{fPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRyLkKxNFch|ryP MkHzV2FPT0WU
MOLT-4 NE\NWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;GUmlEPTB;NECuNlkxOSEQvF2= MVTTRW5ITVJ?
AsPC-1 NV3HSY43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTRyLkS1PFMh|ryP M3rTbnNCVkeHUh?=
HOP-62 NX\SclE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT4UHp3UUN3ME20NE43PTZ6IN88US=> NUjnPXdGW0GQR1XS
A172 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWThRW5XUUN3ME20NE45PTFzIN88US=> NV7pVZFbW0GQR1XS
SN12C MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\KPYVKSzVyPUSwMlk{QDVizszN MoLqV2FPT0WU
MDA-MB-231 NFm3OmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojYTWM2OD12MD65PFk5KM7:TR?= MYXTRW5ITVJ?
RPMI-2650 M3nUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXXe|JKSzVyPUSxMlE2QTNizszN NH;XPGtUSU6JRWK=
KYSE-140 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XKdmlEPTB;NEGuPFEzOyEQvF2= NFXRVYhUSU6JRWK=
KINGS-1 NVq2Z|d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L6OGlEPTB;NEKuOFY6PyEQvF2= Mnv6V2FPT0WU
HSC-3 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm0b5FKSzVyPUSyMlY3PjFizszN Mn\xV2FPT0WU
PC-14 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoraTWM2OD12Mz6xPFgzKM7:TR?= NXX1eIFYW0GQR1XS
COR-L105 Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTR|Lk[1NFIh|ryP M{jwd3NCVkeHUh?=
BE-13 M2\1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHJc4dKSzVyPUS0MlI{PzFizszN NGfmPFRUSU6JRWK=
NCI-H661 NHXCVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVmxZ4JoUUN3ME20OE4zQTV6IN88US=> NWnSWW4{W0GQR1XS
IST-MEL1 M1[yPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzKXY9KSzVyPUS0MlM2QTlizszN MWHTRW5ITVJ?
HCC1806 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHCZZlKSzVyPUS0MlU5PzNizszN NV7GXXUzW0GQR1XS
COLO-800 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX35ZZI3UUN3ME20OE45PDV|IN88US=> NV;0c3RMW0GQR1XS
IST-SL2 MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOzdldKSzVyPUS1MlEzPDdizszN NVHHbFhkW0GQR1XS
8305C MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LYVGlEPTB;NEWuN|A6KM7:TR?= MYDTRW5ITVJ?
UACC-62 MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTR4LkK4O|Uh|ryP Mo\LV2FPT0WU
COR-L23 MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTR5LkG5PUDPxE1? MVfTRW5ITVJ?
EFE-184 NGfYcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f2dWlEPTB;NEeuN|g5KM7:TR?= NVi5OWo5W0GQR1XS
DMS-114 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfwPINKSzVyPUS3MlQyPDlizszN NVjVVll3W0GQR1XS
KYSE-520 NGO1Vo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDzTWM2OD12OD61N|E2KM7:TR?= NXftSJlTW0GQR1XS
SNG-M MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTR7LkSzOEDPxE1? M2jUPHNCVkeHUh?=
A2058 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrjVHZmUUN3ME20PU41QDh3IN88US=> NHLqVlVUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID